Treatment for lipodystrophy
The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (PIs) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.
1. A compound represented by:
2. A pharmaceutical composition comprising a compound of claim 1 .
3. The pharmaceutical composition of claim 2 , further comprising a diluent.
4. A pharmaceutical composition comprising a compound of claim 1 , a stabilizer, a buffering agent, and optionally one or more pharmaceutically acceptable excipients.
5. The pharmaceutical composition of claim 4 , wherein the stabilizer is polacrilin potassium, potassium chloride, or sodium stearyl fumarate.
6. The pharmaceutical composition of claim 4 , wherein the stabilizer is sodium stearyl fumarate.
7. The pharmaceutical composition of claim 4 , wherein the buffering agent is sodium acetate, ammonia, ammonium carbonate, sodium borate, adipic acid, glycine, or monosodium glutamate.
8. The pharmaceutical composition of claim 4 , wherein the buffering agent is ammonia.